REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
06/06/2026
Back to search
Official data from USPTO
ANEMOCYTE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
ANEMOCYTE
ST13
US500000079188650Class
5, 10, 42
Filing
79188650
Registration
5215720
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
61
Latest update
06/07/2026
Trademark type
Word
Nice classes
5, 10, 42
Filing date
09/11/2015
Registration date
06/06/2017
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
02/28/2025
Last transaction
06/07/2026
Responsible office
United States Patent and Trademark Office
Status code
706
Official register
Principal Register
Drawing code
4
Owner type
03
Owner location
GERENZANO (VA), IT
Examiner
SAUNDERS, ANDREA DAWN
Law office
P10
Current location
TMO LAW OFFICE 137
Holders and representatives
Holders
ANEMOCYTE S.R.L.
ARETA INTERNATIONAL S.R.L.
Representatives
Brian A. Tollefson Tollefson IP
Technical classification
Nice Classes
Class 5Class 10Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical and veterinary preparationsrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for use in human and veterinary medicine; chemical preparations for pharmaceutical or medical purposesrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; prescription and non-prescription medicinespillstabletscapsulescapletsliquid dropssachetssyringesinfusion bagsvials and pharmaceutical preparations for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; biological preparations for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; biological preparations for medical and pharmaceutical use for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; chemical preparations for pharmaceutical purposesrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; preparations for diagnostics for medical purposes; drugsrecombinant therapeutic proteinsnucleic acidspeptidescellsgenes and tissues for medical and veterinary purposes; medicines for the treatment of disorders in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; organic products for medical usenatural biomaterials for cell delivery or for augmentation of tissues for medical purposes; biological reagents for medical use; medicinal products based on cells and genessomatic cellsgenetically modified cellsviral vectorsnucleic acids and engineered tissues; products for somatic cell therapyadult stem cellst-cellsb-cellsnk cellsdendritic cellsmonocytesmacrophagesadipocyteskeratinocyteserythrocytesplateletsproducts for gene therapygenetically modified cellsviral vectorsnucleic acids; tissue engineered productscells and tissues that have been subjected to extensive manipulation and are used with the aim to repairreplace or restore a lost or impaired tissue or function; products for regenerative medicinecells and tissues that have been subjected to extensive manipulation and are used with the aim to repairreplacerestore or promote the repairreplacement or regeneration of a lost or impaired tissue or function; products for personalized medicine made of autologous cells or proteins or nucleid acids derived from individual genomic sequences; preparations made up of cells for medical or clinical use; preparations made up of nucleic acidsnucleic acid sequences and chemical reagents for medical purposes; preparations made up of tissuesbiological tissue cultures for medical purposes; vaccines; recombinant proteins supplements; therapeutic kits consisting of therapeutic antibodiesbuffersreagents for use in disease treatment and therapy
Class 10
Surgical apparatus and instruments for medicaldental and veterinary use; medical devices for the introduction of pharmaceutical preparations in the human bodyin particular syringes and catheters; medical equipmentcentrifuges or other separation devices for the isolation of cell sub-populations from tissues and biopsies; surgical apparatus and instruments for medical and veterinary purpose; electrical medical instruments for use in electroporation of cells and tissues for gene transfer purposesboth in vivo and ex-vivo; electronic medical instruments for use in imaging for diagnostic purposes or for monitoring of vital signs of patients
Class 42
Services of laboratory analysis and industrial research in the medical and pharmaceutical fields; research and development in the pharmaceutical and biotechnology fields; research and development in the field of micro-organisms and cells; research and development in biochemistry; scientific research and development in biology; research and development in the field of diagnostic preparations; services of medical laboratories; Providing medical and scientific research information and data on developments in the medical and veterinary fields; scientific and technological servicesscientific research in the field of cancerimmunologyheart and lung conditionsinfectious diseasesophthalmologygenito-urinarycentral nervous systemmusco-skeletalmetabolic diseasesdermatology; consultancy to ensure compliance with quality standards and the design and validation of manufacturing processes in the scientific field and medical technology fields
Publications
History of USPTO decisions and trademark events.
61 publications found
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
06/04/2026
INPS
PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
05/12/2026
INPC
INVALIDATION PROCESSED
05/12/2026
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
03/26/2026
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/28/2025
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
09/30/2025
RNWL
INTERNATIONAL REGISTRATION RENEWED
07/03/2025
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/28/2025
71AG
REGISTERED-SEC.71 ACCEPTED
02/28/2025
INNA
INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
11/15/2024
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
10/25/2024
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
08/21/2024
PR71
POST REGISTRATION ACTION MAILED - SEC.71
02/24/2024
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/12/2024
ES71
TEAS SECTION 71 RECEIVED
06/05/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/24/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/24/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/24/2022
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
10/24/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/24/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/24/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/24/2022
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
06/06/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/09/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
02/22/2018
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/28/2017
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/14/2017
FIMP
FINAL DISPOSITION PROCESSED
09/14/2017
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
09/06/2017
R.PR
REGISTERED-PRINCIPAL REGISTER
06/06/2017
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/21/2017
PUBO
PUBLISHED FOR OPPOSITION
03/21/2017
GPNX
NOTIFICATION PROCESSED BY IB
03/17/2017
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/01/2017
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/01/2017
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/01/2017
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
02/14/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
02/01/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
02/01/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/01/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
02/01/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/01/2017
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/08/2017
GNFR
FINAL REFUSAL E-MAILED
01/08/2017
CNFR
FINAL REFUSAL WRITTEN
01/08/2017
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/22/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/22/2016
ALIE
ASSIGNED TO LIE
12/07/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/16/2016
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/11/2016
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/11/2016
RFNT
REFUSAL PROCESSED BY IB
07/29/2016
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/13/2016
RFRR
REFUSAL PROCESSED BY MPU
07/13/2016
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/12/2016
MAFR
APPLICATION FILING RECEIPT MAILED
07/12/2016
CNRT
NON-FINAL ACTION WRITTEN
07/11/2016
DOCK
ASSIGNED TO EXAMINER
07/08/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/08/2016
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/07/2016
Continuous trademark protection
Get notified about every new filing that threatens ANEMOCYTE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.